Carvalho Carolina Teixeira, Pinto Marta Mesquita, Plácido Ana Neto, Martins Ana
Oncology Unit, Centro Hospitalar Lisboa Ocidental-HSFX, Lisbon, Portugal.
BMJ Case Rep. 2015 Apr 24;2015:bcr2014208904. doi: 10.1136/bcr-2014-208904.
Basal cell carcinoma (BCC) is the most common malignancy worldwide. BCC has a benign evaluation, despite the high rate of local recurrence. Conversely, metastatic BCC (mBCC) is extremely rare. In this article, we present a case of an 86-year-old woman with a history of forearm mBCC, excised in 2009. In 2011, she experienced a left axilla enlargement and the evaluation revealed metastasis of mBCC. The patient began chemotherapy but had regional progression. After she had undergone radiotherapy, initiation of a clinical phase II trial was proposed, which she refused. The patient died in March 2013, 17 months after metastases diagnosis. mBCC poses a significant management challenge and current treatment options are limited. The gold standard treatment is surgical excision. Given the rarity of metastatic spread of cancer and the limited effectiveness of cytostatic agents, it has been a challenge to treat these types of patients.
基底细胞癌（BCC）是全球最常见的恶性肿瘤。尽管局部复发率很高，但BCC的评估结果为良性。相反，转移性基底细胞癌（mBCC）极为罕见。在本文中，我们报告了一例86岁女性患者，她有前臂mBCC病史，于2009年接受了切除手术。2011年，她出现左腋窝肿大，评估显示为mBCC转移。患者开始化疗，但病情出现局部进展。在她接受放疗后，有人提议启动一项临床II期试验，但她拒绝了。该患者于2013年3月去世，即转移诊断后的17个月。mBCC带来了重大的治疗挑战，目前的治疗选择有限。金标准治疗方法是手术切除。鉴于癌症转移扩散的罕见性以及细胞毒性药物的有效性有限，治疗这类患者一直是一项挑战。
